Project description DEENESFRITPL Machine learning-based platform for the management of diabetes Diabetes is growing globally, with a forecast for 642 million affected people in 2040. Proper management of this chronic disease can prevent complications and improve patients’ quality of life. The Icelandic company Medilync is developing innovative software that employs machine learning to efficiently use data generated for diabetic patients and obtain the information that helps improve glycaemic control. The created knowledge will be shared in the patient-centred care circle that includes doctors and other healthcare professionals. The company developed machine learning models that will be trained and validated with real data from patients. The EU-funded INSULYNC project will finalise and validate the platform with key stakeholders and prepare a business strategy for the European market. Show the project objective Hide the project objective Objective Medilync is a start-up based in Iceland and founded in 2012 with the goal of revolutionizing the management and treatment of diabetes. Medilync has created a medical device that simplifies the way patients manage glucose measurement and insulin delivery. Diabetes requires a highly-disciplined routine of glucose control and insulin injections, being lack of accuracy and of recordkeeping one of the main reasons for a deteriorating health. There are about 60 million people with diabetes in the EU and this number will rise to 71 million by 2040. Up to 75% of all people with diabetes are not in good control of their condition, leading to huge social and economic costs. 40% of diabetes patients are >65 years, and need to involve family members, friends and providers in real-time to improve adherence to treatment. Medilync brings the first all-in-one medical device, INSULYNC, which allows for easy blood glucose measuring, recording of the injection of insulin, and real-time delivery of all this information for storage on a cloud computing system, Cloudlync, sharing it with the doctor and the patient’s family. INSULYNC and Cloudlync are highly integrated to help the patient keep track of medication and to organize all data relative to diabetes management under one single system. The solution helps patients to engage with family and doctors (improves treatment adherence by 35%), with the result of patients spending less (could save around €40 billion a year to European healthcare systems) and being in better health. The overall objectives of this project include finalizing and validating INSULYNC and Cloudlync with key stakeholders (e.g. clinical trials in key target markets), and preparing our entry strategy into the European market. Through this project we aim to boost the growth of our company and obtain €14.17M revenues (overall profit of 55%), while creating 30 new jobs by 2025, with a ROI of €4.9 per euro invested. Fields of science medical and health scienceshealth scienceshealth care serviceseHealthnatural sciencescomputer and information sciencessoftwaremedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicineendocrinologydiabetesnatural sciencescomputer and information sciencesartificial intelligencemachine learning Programme(s) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator MEDILYNC EHF Net EU contribution € 50 000,00 Address Hilmisgata 4 900 Vestmannaeyjar Iceland See on map Region Ísland Ísland Landsbyggð Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
